GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnax Lab Ltd (BOM:506128) » Definitions » COGS-to-Revenue

Parnax Lab (BOM:506128) COGS-to-Revenue : 0.51 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Parnax Lab COGS-to-Revenue?

Parnax Lab's Cost of Goods Sold for the three months ended in Mar. 2024 was ₹238 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹464 Mil.

Parnax Lab's COGS to Revenue for the three months ended in Mar. 2024 was 0.51.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Parnax Lab's Gross Margin % for the three months ended in Mar. 2024 was 48.74%.


Parnax Lab COGS-to-Revenue Historical Data

The historical data trend for Parnax Lab's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnax Lab COGS-to-Revenue Chart

Parnax Lab Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.67 0.71 0.53 0.54

Parnax Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.56 0.51 0.59 0.51

Parnax Lab COGS-to-Revenue Calculation

Parnax Lab's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1028.144 / 1887.112
=0.54

Parnax Lab's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=237.695 / 463.693
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Parnax Lab  (BOM:506128) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Parnax Lab's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 237.695 / 463.693
=48.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Parnax Lab COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Parnax Lab's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnax Lab (BOM:506128) Business Description

Traded in Other Exchanges
N/A
Address
104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.

Parnax Lab (BOM:506128) Headlines

No Headlines